葛兰素史克Glaxosmithkline（GSK）2024年社会和治理报告「LSE」（英文版）（14页）.pdf

1、1 March 2025Basis of Reporting Social&Governance 2024Table of ContentsBasis of Reporting 2Governance of Changes to Published Data 2Data Management 2Data Collection and Documentation 2High Level Description of Nature of Metrics 2Detailed Description of Metrics 2Access 3US Patient Assistance Programs(

2、PAP People reach)3US PAP Value of GSK medicine and vaccines 3Total community investment 3Product reach (doses supplied to lower income countries(millions(m)3Product reach (people reached in lower income countries in thousands(000s)4Global health and health security 5Number of assets Global Health pi

3、peline to address priority WHO diseases 5Number of active R&D projects to address prioritised pathogens 6Inclusion and diversity 7Year-on-year spend with US-based certified diverse-owned suppliers 7Representative clinical studies 7Gender and ethnicity 7Ethical standards 8%of employees and complement

4、ary workers that complete GSKs mandatory training 8Employees who believe they Can and Do Speak Up”8High-risk suppliers Achieving minimum EcoVadis score 9Ethical conduct 9Product governance 11Regulatory Inspections 11Product Recalls 11Trial protocol and result summaries 12PeopleHealth and safety 12Ov

5、erall employee turnover 14Glossary of Terms 142 March 2025Basis of ReportingGSK has identified six focus areas that address what is most material to our business and the issues that matter the most to our stakeholders.These focus areas are core to our strategy and are where we can have the greatest

6、positive impact on some of societys most urgent challenges:Access Global health and health security Environment Inclusion and Diversity Ethical standards Product governanceThis document gives the Basis of Reporting for selected metrics contributing to Performance Rating metrics and/or in scope of li